Dr. Sepesi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
499 E Hampden Ave
Ste 200
Englewood, CO 80113Phone+1 303-409-1430Fax+1 303-781-2218
Education & Training
University of Texas MD Anderson Cancer Center/University of Texas Medical School at HoustonFellowship, Thoracic Surgery, 2011 - 2013
University of RochesterResidency, Surgery, 2005 - 2011
University of ColoradoResidency, Internal Medicine, 2004 - 2004
Jagiellonian University Medical CollegeClass of 2004
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 2013 - 2026
CO State Medical License 2023 - 2025
OK State Medical License 2020 - 2021
NY State Medical License 2008 - 2013- American Board of Surgery Surgery
- American Board of Thoracic Surgery Thoracic and Cardiac Surgery
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma Start of enrollment: 2019 Oct 02
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 592 citationsLocal consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line...Daniel R. Gomez, George R. Blumenschein, J. Jack Lee, Mike Hernandez, Rong Ye
The Lancet. Oncology. 2016-12-01 - 77 citationsPreoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer.Jamie E Chaft, Yu Shyr, Boris Sepesi, Patrick M Forde
Journal of Clinical Oncology. 2022-02-20 - 20 citationsNeoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis.Mark Sorin, Connor Prosty, Louis Ghaleb, Kathy Nie, Khaled Katergi
JAMA Oncology. 2024-05-01
Authored Content
- My Top 5 Most Practice-Changing Presentations at WCLCOctober 2018
Press Mentions
Foundation Medicine Partners with Lung Cancer Research Foundation and the Lung Cancer Mutation Consortium on Screening Trial to Enable Precision TherapyJune 3rd, 2022- Circulating Cellular Determinants to Predict Response to Anti-PD-1 Monotherapy in Patients with Malignant Pleural MesotheliomaMay 15th, 2022
- Adding Atezolizumab to Neoadjuvant Cisplatin-Pemetrexed a Feasible Option in Malignant Pleural MesotheliomaOctober 15th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
